

Date: October 30, 2026

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051
Maharashtra, India.

Symbol: FABTECH

BSE Limited

Listing Department
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India.

Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026.

Request you to take the same on record.

Thank you.

**Yours faithfully,
For Fabtech Technologies Limited**

Hemant
Mohan
Anavkar

Digitally signed
by Hemant
Mohan Anavkar
Date: 2026.10.30
07:36:01 +05'30'

**Hemant Mohan Anavkar
Executive Director
DIN: 00150776**

Encl.: As mentioned above

FABTECH TECHNOLOGIES LIMITED

Engineering the capability behind the future of healthcare

Integrated | Global | Asset Light | Engineering led

Pharma | Biotech | Healthcare | Advanced Manufacturing



Design & Build



Enabling Science



Engineering life

Disclaimer


This document has been prepared for information purposes only and is not an offer or invitation or recommendation to buy or sell any securities of **Fabtech Technologies Ltd**, nor shall part, or all, of this document form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company.

This document is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this document is being provided by the Company and is subject to change without notice. The Company relies on information obtained from sources believed to be reliable but does not guarantee its accuracy or completeness.


This document contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this document that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the document. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

About Us



Core systems manufactured in-house under one roof, ensuring control over quality, speed & cost



62+ Countries

2000+ Specialized Installations

500+ Projects Delivered

₹900+ Cr Order Book (as of 30th Sept 2026)

~75-80% of Revenue from MENA, GCC & ECO Zone markets



Performance Highlights



Business Highlights

Strong EBITDA Growth

EBITDA (incl. other income) more than doubled **QoQ, up 110%** to **₹155.7 mn** in Q2 FY27.

Revenue Recovery Expected in H2

Revenue and profitability are expected to improve as planned project milestones translate into execution during H2 FY27

New Market Entry

The Company enters a CIS country with a new turnkey design-and-build project.

Improved Profitability Outlook

Management remains confident of achieving its FY27 Adjusted PAT* margin objective of 8–9%.

*Adjusted PAT excludes exceptional items

International Industry Engagement

Participation in CPHI Milan 2026 provided an opportunity to engage with pharmaceutical industry stakeholders and explore potential project opportunities



Operational Update

Business resilience & momentum



H1 navigated geopolitical uncertainty and freight volatility across GCC markets.



Q2 UAE operations demonstrated remarkable progress and strong order traction despite regional conditions. Continuity of operations, deliveries and customer commitments was maintained despite higher costs.



Installation continued with enhanced security and protective measures for site teams, resulting in significant additional installation costs.



Africa initiatives are gaining momentum, including cell and gene therapy (CGT) and other advanced-technology facility projects.

Order book & growth visibility



Healthy order book: Rs. 900 crore (2.2x FY26 Revenue)



Additional prospective orders from Africa and Saudi Arabia: Rs. 800-850 crore. The existing order position provides meaningful visibility over the next 12 months.



Africa is expected to be a significant contributor to H2 project execution and revenue.



Accelerate project delivery and business development across Africa and the UAE while managing Saudi project timelines.



Advance capabilities in cell and gene therapy facilities, other high-technology projects and data-centre infrastructure.



Maintain disciplined execution, cost control and customer commitments.

Consolidated Income Statement – Q2/H1 FY27

Particulars (INR Mn)	Q2FY27	Q1FY27	Q2FY26	QoQ%	H1FY27	H1FY26
Revenue From Operations	920.9	749.8	1,214.8	22.8	1,670.7	1,894.9
Other Income	54.5	31.7	28.0	72.2	86.2	37.4
Total Income	975.4	781.5	1,242.8	24.8	1,756.9	1,932.3
Total Expenditure	819.7	707.4	910.3	15.9	1,527.1	1,652.5
EBITDA	155.7	74.1	332.5	110.0	229.8	279.8
EBITDA Margin (%)	16.0	9.5	26.8	647 bps	13.1	14.5
Reported PAT	150.2	42.1	281.1	256.9	192.4	219.8
Reported PAT Margin (%)	16.3	5.6	23.1	1,070 bps	11.5	11.6
Adjusted PAT**	84.3	42.1	281.1	99.1	126.5	202.1
Adjusted PAT Margin	9.2	5.6	23.1	354 bps	7.6	10.7
Earnings Per Share (Rs)*	3.38	0.95	8.68		4.33	6.79

**Adjusted PAT excludes exceptional items (net of tax) of INR 65.9 Mn in Q2 & H1 FY27 & INR 17.7 Mn in H1 FY26.

*The Company issued approximately 1.20 crore equity shares through its IPO in October 2025.

Strategic Priorities



01

Accelerate project delivery and business development across Africa and the UAE while managing Saudi project timelines.



02

Advance capabilities in cell and gene therapy facilities, other high-technology projects and data-centre infrastructure.



03

Exploring an operational opportunity in Europe targeting Q4 FY27 or Q1 FY28, subject to due diligence and approvals.



04

Maintain disciplined execution, cost control and customer commitments.

H1FY27: Deepening Local Presence

Market By Market

H1FY27 GEOGRAPHIC REVENUE MIX



SAUDI ARABIA
+18.5% YoY

₹462.3 mn in
H1 FY27



AFRICA
~₹470 Mn

Morocco, Kenya & Algeria
combined





CORE FTL BUSINESS
Turnaround

A strong standalone recovery in the core
business alongside the international
scale-up.

Enhancing International Visibility



Participated in CPHI Milan 2026
engaging with global
pharmaceutical industry and
exploring potential business
opportunities.



FABTECH 4.0

From engineering execution to technology-enabled project delivery



Digital
Engineering



Project
Intelligence



Integrated
Procurement



Global
Collaboration



Real-Time
Execution

Scalable execution model

Building the infrastructure behind the next generation of healthcare manufacturing.

Projects backed by LCs provide greater payment security, supporting execution confidence.



Five Structural Drivers



Structural Healthcare Capex

Pharma and healthcare manufacturing capacity is expanding across emerging markets.



Integrated Capability

Process + Air + Water under one engineering platform.



Global Localization

Countries are increasingly building domestic pharmaceutical manufacturing capabilities.



Large Revenue Visibility

₹900+ crore open order book as of Sept 2026.



Emerging Infrastructure Opportunities

Expanding into advanced facilities, including cell & gene therapy, high-containment and data centres.

Fabtech is positioned at the intersection of healthcare infrastructure, manufacturing localization and specialized engineering

The Real Moat

Globalization is a Core Growth Engine

Five Capabilities → A High-Value Engineering Proposition


Global execution
62-country experience and **growing local presence.**

Validation capability
Critical for regulated pharmaceutical environments.

Engineering know-how
Complex regulated environments.

Integrated execution
Multiple systems under one partner.

In-house manufacturing
Greater control over quality, cost and timelines.



62+
Countries

2000+
Specialized Installations

500+
Projects Delivered

Building local execution ecosystems in high-growth healthcare markets.

The Core Capabilities

Six Core Capability Domains, Developed In-House

Every solution is custom-designed and built at our own facilities — covering OSD, sterile liquids, vaccines, oncology, hormones & biosimilars.



Cleanroom

Modular & bio-cleanrooms, HVAC and internal infrastructure.



Water & Utilities

Purified water, pure steam and WFI generation and distribution.



Sterilization

Air & contained sterilization, tunnels and cleanroom equipment.


Process

Powder processing, OSD & tablet coating, lab to production scale.



Containment

Isolation & containment for process, packaging and QC/QA.



Custom-built


Designed & manufactured in-house for each client's challenge.




We don't build buildings. We build the critical infrastructure inside them

One Stop Solution for the entire lifecycle

One platform. Multiple critical systems. One accountable partner.



One-Stop Turnkey Solution



Customers reduce coordination complexity by working with an integrated engineering partner like us...

Not just “build to drawing” — design, engineer and deliver the complete solution.

Need for Fabtech's Expertise

Fabtech is building the critical infrastructure layer for global pharmaceutical manufacturing.



Industry
Structural
Change



Customer
Problem



Fabtech
Capability



Competitive
Advantage



Global
Expansion



Order Book
Evidence



Financial
Inflection



Scalable growth
Model

Integrated Execution

Integrated control across the value chain supports delivery discipline, quality and execution visibility.

Turnkey Execution

(+)

Design & Build

(+)

In-house Manufacturing



Greater Execution Control

KEY STRATEGIC ADVANTAGES



Single-point accountability

One integrated delivery structure reduces coordination interfaces across design, manufacturing, installation and validation.



Control over critical systems

In-house Process, Air & Water capabilities provide greater control over specifications, quality, integration and delivery.



Faster & more predictable execution

Lower dependence on fragmented external sourcing can support shorter lead times and greater schedule visibility.



Integrated quality & compliance

Design-to-validation integration enables quality and applicable regulatory requirements to be addressed throughout execution.

Solutions for Air

Comprehensive Clean Air & Containment Solutions

Built Environment

- + Modular Cleanrooms
- + Bio-Cleanrooms
- + HVAC & Cleanroom Infrastructure

Containment Solutions

- + Aseptic & Non-Aseptic Isolators
- + Sterility Testing, Filling & Dispensing
- + Sampling & Process Containment

Clean-air Equipment

- + LAF Workbench, Vertical LAF & Mobile LAF Trolleys
- + Air & Mist Showers
- + Passboxes, Dedusting Tunnels & Booths



Solutions for Water

Comprehensive Water & Utility Solutions



+ Purified Water Generation & Distribution



+ Water for Injection (WFI)



+ Pure Steam Generation & Distribution



+ Process Vessels



+ CIP & SIP Systems



+ Chilled Water



+ Utilities System

Flow Rates
Ranging from
500–50,000
LPH

Solutions for Processes

Smart Solutions for Pharma Processes



OSD processing

High Shear Mixer

Fluid Bed Suite

Closed Loop Granulator & Blenders

Coaters, Particle Sizers & Other Ancillaries



Fill & Finish


Prefilled Syringe
Machine

Vial Filling & Capping
Machine





Business Overview

Scaling through in-house arms and strategic partners.



Global Presence

Global engineering, local execution




India
Engineering & manufacturing base


UAE
Regional HQ & Local team for sales, service, execution


Saudi Arabia
ICV (In Country Value) local team for installation commissioning and KSA JV


Jordan
MENA project delivery


Egypt
Local Team for Cleanroom Projects Delivery


Algeria
North Africa Sales & Maintenance Office


Nigeria
West Africa expansion

GCC · MENA · Africa · CIS
Core growth corridor

Turnkey Projects:

Delivering Critical Manufacturing Infrastructure

Selected projects demonstrate Fabtech's ability to execute complex pharmaceutical manufacturing infrastructure across global markets

FIDSON HEALTHCARE



Nigeria

15-month Commissioning

Key Scope

- + Vaccine/Pharma Facility
- + R&D Centre
- + Modular Cleanrooms
- + 150 HVAC Units
- + Utility Piping
- + MEP
- + High-purity water
- + Fire & Safety



HIMALAYA WELLNESS



UAE

Pharmaceutical Manufacturing Facility

Key Scope

- + Nutraceutical OSD and Liquid facility.
- + Cleanroom requirements.
- + Design, Installation & Validation
- + Completed in **Less Than 1 Year**



MECHNIKOV S.A.



Nicaragua

9,000 sq. m. | Up to 30 Mn doses/year

Key Scope

- + R&D Facility + Vaccine Manufacturing Unit
- + Project Planning & Execution
- + End-to-End Commissioning
- + Technical Improvements



SUDAIR PHARMA



Saudi Arabia

6,285 sq. m. | Facility Operational

Key Scope

- + Low-side turnkey scope
- + Cleanrooms
- + HVAC
- + Clean Utilities
- + Bio-cleanroom
- + Containment & isolators
- + BMS/EMS
- + High-purity water
- + Electromechanical



From facility infrastructure to commissioning, Fabtech has executed complex turnkey projects across regulated pharma markets.

Clientele



Way Forward



TAM (Total Addressable Market)

A large, structurally-funded addressable market

Fabtech's scope covers **60%+ of project spend** — Air, Water, Process, Cleanrooms and Utilities.

Global TAM

\$180B

Turnkey pharma & biotech projects, growing at ~8% CAGR.

Fabtech SAM

\$28–30B

Core geographies: GCC, Africa & MENA.

KSA Build-Out

\$15B+

Pharma manufacturing investment planned to 2030.

Africa

\$60B+

Medicine-production facilities, WHO / Global Fund backed to 2040.

Source: Grand View Research (Pharmaceutical Manufacturing Market Report); regional capex estimates.

The Pharma Self-Reliance Super-Cycle

Healthcare localization is creating a bigger opportunity

Global pharma supply-chain diversification



National manufacturing ambitions



New pharma plants



Biotech / vaccine facilities



Cleanroom + HVAC + Utilities

Future adjacency

Data
Centres


Renewable
Energy

High-spec
manufacturing

CGT projects
in the GCC



Driving Growth



Margin expansion is expected to be driven by glocalization, sourcing optimization and improved project execution.

Annual Highlights



Key Annual Highlights (1/2)



The Company delivered a revenue CAGR of **28%** and an earnings CAGR of **22%** over FY23–FY26.



The closing unexecuted order book stood at **Rs 900 Cr** at the end of FY26, led by order inflow of **Rs 500+ Cr** during the year, executable over **12–18 months**.



Gross receivables stood at **Rs 204 Cr** against which advance from customers stood at **Rs 47 Cr** as at **31st March 2026**.



The Company works against **LCs** on all international projects.




Strong order momentum in GCC, MENA and ECO Zone markets, with order contribution rising from **83% to 94%**.




Key Annual Highlights (2/2)

Region wise split of Orders (FY26)




~94% of Order Intake Driven by GCC, MENA & ECO Regions

Revenue (INR Mn)



EBITDA (INR Mn)



Consolidated Income Statement

Particulars (INR Mn)	FY23	FY24	FY25	FY26
Revenue From Operations	1,938.0	2,261.4	3,266.7	4,107.7
Other Income	61.1	44.7	92.7	205.6
Total Income	1,999.1	2,306.0	3,359.4	4,313.3
Total Expenditure	1,686.9	1,922.3	2,889.8	3,757.7
EBITDA	312.2	383.7	469.7	555.6
EBITDA Margin (%)	15.6	16.6	14.0	12.9
Reported PAT	213.2	272.2	464.5	383.5
PAT Margin (%)	11.0	12.0	14.2	9.3
Earnings Per Share (Rs)	6.61	8.43	14.34	10.00

29%

Total Income
CAGR

22%

Net Profit
CAGR

Consolidated Balance Sheet

Particulars (INR Mn)	FY25	FY26	H1FY27
<u>Equity & Liabilities</u>			
Equity			
Share Capital	323.9	444.5	444.5
Other Equity	1,407.2	3,753.2	3946.3
Non-controlling Interest	-0.0	-0.0	0.0
Total Equity	1,731.1	4,197.7	4,390.8
<u>Liabilities</u>			
Long-Term Borrowings	5.3	5.3	3.9
Lease liabilities	266.2	249.0	237.8
Long-Term Provisions	8.2	16.6	18.3
Total Non-Current Liabilities	279.7	270.9	260.0
Short-Term Borrowings	540.9	422.0	309.0
Lease liabilities	25.9	20.1	21.3
Trade payables	988.0	1,053.7	836.5
Other financial liabilities	2.8	31.0	33.2
Other current liabilities	629.5	488.5	960.7
Short-Term Provisions	8.7	4.0	4.8
Current tax liabilities (net)	58.9	49.1	41.1
Total Current Liabilities	2,254.7	2,068.5	2,206.8
Total Equity & Liabilities	4,265.6	6,537.0	6,857.6

Particulars (INR Mn)	FY25	FY26	H1FY27
<u>Assets</u>			
Property Plant & Equipment	263.4	289.2	274.1
Goodwill	370.0	229.7	241.9
Right of use assets	301.5	259.8	234.5
Intangible Assets	6.5	2.4	2.1
Non-Current Investments	83.2	159.3	160.0
Long-Term Loans & Advances	12.9	78.1	79.5
Other Non-Current Assets	65.1	259.3	105.7
Deferred tax assets (net)	24.3	38.7	67.2
Total Non-Current Assets	1,126.9	1,316.5	1,165.0
Inventories	594.2	213.4	184.8
Investments	64.3	97.6	129.3
Trade Receivables	1,507.4	2,043.4	2,261.0
Cash & Cash Equivalents	350.1	2,085.7	1,699.7
Short Term Loans & Advances	22.5	1.3	384.0
Other financial assets	355.0	369.3	2.0
Current tax assets (net)	0.5	1.6	292.6
Other Current Assets	188.5	351.9	739.3
Total Current Assets	3,082.4	5,164.2	5,692.6
Assets held for sale	56.3	56.3	-
Total Assets	4,265.6	6,537.0	6,857.6

Thank You!

FABTECH TECHNOLOGIES LTD.

(E): cs@fabtechnologies.com

www.fabtechnologies.com

KAPTIFY[®] Consulting

Strategy & Investor Relations | Consulting

(E): contact@kaptify.in

(T): +91-845 288 6099

www.kaptify.in

